Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Other Accumulated Expenses (2019 - 2025)

Nanobiotix has reported Other Accumulated Expenses over the past 7 years, most recently at $7.9 million for Q2 2025.

  • For Q2 2025, Other Accumulated Expenses rose 1.2% year-over-year to $7.9 million; the TTM value through Jun 2025 reached $7.9 million, up 1.2%, while the annual FY2024 figure was $8.1 million, 1.78% down from the prior year.
  • Other Accumulated Expenses for Q2 2025 was $7.9 million at Nanobiotix, down from $8.1 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $8.2 million in Q4 2023 and troughed at $6.3 million in Q4 2021.
  • A 5-year average of $7.4 million and a median of $7.8 million in 2024 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: decreased 24.43% in 2021 and later grew 18.52% in 2022.
  • Year by year, Other Accumulated Expenses stood at $6.3 million in 2021, then grew by 10.53% to $7.0 million in 2022, then increased by 17.34% to $8.2 million in 2023, then decreased by 1.78% to $8.1 million in 2024, then decreased by 1.7% to $7.9 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for NBTX at $7.9 million in Q2 2025, $8.1 million in Q4 2024, and $7.8 million in Q2 2024.